JP2023519100A5 - - Google Patents

Info

Publication number
JP2023519100A5
JP2023519100A5 JP2022548596A JP2022548596A JP2023519100A5 JP 2023519100 A5 JP2023519100 A5 JP 2023519100A5 JP 2022548596 A JP2022548596 A JP 2022548596A JP 2022548596 A JP2022548596 A JP 2022548596A JP 2023519100 A5 JP2023519100 A5 JP 2023519100A5
Authority
JP
Japan
Prior art keywords
antibody
seq
group
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519100A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/017427 external-priority patent/WO2021163170A1/en
Publication of JP2023519100A publication Critical patent/JP2023519100A/ja
Publication of JP2023519100A5 publication Critical patent/JP2023519100A5/ja
Pending legal-status Critical Current

Links

JP2022548596A 2020-02-11 2021-02-10 抗acvr1抗体およびその使用 Pending JP2023519100A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062975047P 2020-02-11 2020-02-11
US62/975,047 2020-02-11
US202063030131P 2020-05-26 2020-05-26
US63/030,131 2020-05-26
PCT/US2021/017427 WO2021163170A1 (en) 2020-02-11 2021-02-10 Anti-acvr1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2023519100A JP2023519100A (ja) 2023-05-10
JP2023519100A5 true JP2023519100A5 (cg-RX-API-DMAC7.html) 2024-02-22

Family

ID=74860418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548596A Pending JP2023519100A (ja) 2020-02-11 2021-02-10 抗acvr1抗体およびその使用

Country Status (11)

Country Link
US (2) US11945872B2 (cg-RX-API-DMAC7.html)
EP (1) EP4103617A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023519100A (cg-RX-API-DMAC7.html)
KR (1) KR20220140802A (cg-RX-API-DMAC7.html)
CN (1) CN115362175A (cg-RX-API-DMAC7.html)
AU (1) AU2021218675A1 (cg-RX-API-DMAC7.html)
CA (1) CA3167441A1 (cg-RX-API-DMAC7.html)
IL (1) IL295419A (cg-RX-API-DMAC7.html)
MX (1) MX2022009769A (cg-RX-API-DMAC7.html)
WO (1) WO2021163170A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202208222B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019364415A1 (en) 2018-10-23 2021-05-20 Keros Therapeutics, Inc. ALK2 antibodies and methods of use thereof
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
CN119529092A (zh) * 2021-09-03 2025-02-28 来凯医药科技(上海)有限公司 抗acvr2a抗体及其用途
WO2024092133A1 (en) 2022-10-27 2024-05-02 Regeneron Pharmaceuticals, Inc. Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
CN101160055A (zh) * 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US8859752B2 (en) 2006-04-18 2014-10-14 The Trustees Of The University Of Pennsylvania SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
US8895711B2 (en) * 2006-04-18 2014-11-25 The Trustees Of The University Of Pennsylvania Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
RS53258B (sr) 2007-02-21 2014-08-29 University Of Massachusetts Humana antitela protiv virusa hepatitisa c (hcv) i njihove upotrebe
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素a之抗體及其用途
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
US9840557B2 (en) * 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof
WO2016121908A1 (ja) * 2015-01-30 2016-08-04 学校法人埼玉医科大学 抗alk2抗体
CN111836643A (zh) 2018-03-05 2020-10-27 学校法人埼玉医科大学 用于治疗或预防异位骨化的药物组合物
KR20210038906A (ko) * 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
AU2019364415A1 (en) 2018-10-23 2021-05-20 Keros Therapeutics, Inc. ALK2 antibodies and methods of use thereof
US12428484B2 (en) 2018-12-06 2025-09-30 Alexion Pharmaceuticals, Inc. Anti-ALK2 antibodies and uses thereof
EP4008350A4 (en) 2019-07-26 2023-06-14 Saitama Medical University ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1

Similar Documents

Publication Publication Date Title
JPWO2018147245A1 (ja) 抗gprc5d抗体及び該抗体を含む分子
CA3118775A1 (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
JP2021526022A5 (cg-RX-API-DMAC7.html)
JP2018108081A5 (cg-RX-API-DMAC7.html)
JP2026050358A (ja) 治療用抗cd40リガンド抗体
JP2013056885A5 (cg-RX-API-DMAC7.html)
JP2020537520A5 (cg-RX-API-DMAC7.html)
WO2011023130A1 (zh) 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
JP2020515277A5 (cg-RX-API-DMAC7.html)
TW202140553A (zh) C5ar1抗體分子及其用途
TWI797609B (zh) 抗pd-1和pd-l1的四價雙特異性抗體
KR20240049318A (ko) Fap/cd40 결합 분자 및 이의 의학적 용도
JP2021528364A (ja) 抗bcma抗体及びその用途
JP2022501065A5 (cg-RX-API-DMAC7.html)
JP2022528007A (ja) PDL1及びTGFβに対する二機能性融合タンパク質並びにその使用
JP2024517931A5 (cg-RX-API-DMAC7.html)
TW202502822A (zh) Egfr/c-met雙特異性結合蛋白及其用途
WO2021259335A1 (en) Human monoclonal antibodies against tigit for immune related diseases
JP2019518473A5 (cg-RX-API-DMAC7.html)
TW202309076A (zh) 用於治療α-突觸核蛋白病之抗體
TWI877824B (zh) 結合人cd39的抗體或其抗原結合片段、其製備方法及用途
US10584175B2 (en) FN14-binding proteins and uses thereof
JP2023551983A5 (cg-RX-API-DMAC7.html)
CN117715940A (zh) 抗trem-1抗体
TWI773264B (zh) 結合人ngf的抗體、其製備方法和用途